Appili Therapeutics Inc. (TSE:APL) to Post FY2023 Earnings of ($0.09) Per Share, Zacks Small Cap Forecasts
Appili Therapeutics Inc. (TSE:APL) to Post FY2023 Earnings of ($0.09) Per Share, Zacks Small Cap Forecasts
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Equities researchers at Zacks Small Cap boosted their FY2023 earnings estimates for shares of Appili Therapeutics in a note issued to investors on Thursday, September 1st. Zacks Small Cap analyst D. Bautz now anticipates that the company will post earnings per share of ($0.09) for the year, up from their previous estimate of ($0.10).
Appili治療公司(多倫多證券交易所股票代碼:APL-GET評級)--在9月1日星期四發給投資者的一份報告中,Zack Small Cap的股票研究人員上調了他們對Appili治療公司股票2023財年的收益預期。扎克斯小盤分析師D.Bautz現在預計,該公司今年的每股收益將為0.09美元,高於此前預測的0.10美元。
Appili Therapeutics (TSE:APL – Get Rating) last issued its quarterly earnings data on Friday, August 12th. The company reported C($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of C($0.03). The business had revenue of C$0.01 million for the quarter.
Appili Treateutics(多倫多證券交易所股票代碼:APL-GET Rating)最近一次發佈季度收益數據是在8月12日星期五。該公司公佈本季度每股收益(EPS)為0.03加元,超過了普遍預期的0.03加元。該業務本季度的收入為10萬加元。
Appili Therapeutics Stock Performance
阿普利治療公司股票表現
Further Reading
進一步閲讀
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 隨着管理層重組,股市能否迅速反彈?
- MarketBeat:回顧中的一週8/29-9/2
- 霍梅爾在這些水平上看起來很便宜
- 露露檸檬將飆升至9月
- 耐克股票會被超賣,但仍被高估嗎?
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《阿普利治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Appili Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。